一种结合 G-四链体的小分子与 HDAC 抑制剂 SAHA(伏立诺他)在吉西他滨敏感和耐药的胰腺癌细胞中协同作用。
A G-Quadruplex-Binding Small Molecule and the HDAC Inhibitor SAHA (Vorinostat) Act Synergistically in Gemcitabine-Sensitive and Resistant Pancreatic Cancer Cells.
机构信息
School of Pharmacy, University College London, London WC1N 1AX, UK.
出版信息
Molecules. 2020 Nov 19;25(22):5407. doi: 10.3390/molecules25225407.
The stabilisation of G-quadruplexes (G4s) by small-molecule compounds is an effective approach for causing cell growth arrest, followed by cell death. Some of these compounds are currently being developed for the treatment of human cancers. We have previously developed a substituted naphthalene diimide G4-binding molecule (CM03) with selective potency for pancreatic cancer cells, including gemcitabine-resistant cells. We report here that CM03 and the histone deacetylase (HDAC) inhibitor SAHA (suberanilohydroxamic acid) have synergistic effects at concentrations close to and below their individual GI values, in both gemcitabine-sensitive and resistant pancreatic cancer cell lines. Immunoblot analysis showed elevated levels of γ-H2AX and cleaved PARP proteins upon drug combination treatment, indicating increased levels of DNA damage (double-strand break events: DSBs) and apoptosis induction, respectively. We propose that the mechanism of synergy involves SAHA relaxing condensed chromatin, resulting in higher levels of G4 formation. In turn, CM03 can stabilise a greater number of G4s, leading to the downregulation of more G4-containing genes as well as a higher incidence of DSBs due to torsional strain on DNA and chromatin structure.
小分子化合物稳定 G-四链体(G4s)可有效诱导细胞生长停滞,随后导致细胞死亡。目前,其中一些化合物正被开发用于治疗人类癌症。我们之前开发了一种取代的萘二酰亚胺 G4 结合分子(CM03),对包括吉西他滨耐药细胞在内的胰腺癌细胞具有选择性作用。我们在此报告,CM03 和组蛋白去乙酰化酶(HDAC)抑制剂 SAHA(丁氧羰基羟胺)在接近和低于各自 GI 值的浓度下,在吉西他滨敏感和耐药的胰腺癌细胞系中具有协同作用。免疫印迹分析显示,药物联合治疗后γ-H2AX 和 cleaved PARP 蛋白水平升高,表明 DNA 损伤(双链断裂事件:DSBs)和凋亡诱导水平分别增加。我们提出,协同作用的机制涉及 SAHA 使浓缩染色质松弛,从而导致更高水平的 G4 形成。反过来,CM03 可以稳定更多的 G4,导致更多含有 G4 的基因下调,以及由于 DNA 和染色质结构的扭转应变导致更高的 DSB 发生率。